United States: HIPAA/HITECH Omnibus Final Rule: Implications For Research

Last Updated: February 8 2013
Article by Robyn S. Shapiro and Julie Rusczek

The Department of Health and Human Services' HIPAA/HITECH Omnibus Final Rule (Final Rule) includes a number of provisions that will alleviate certain restrictions and administrative burdens in human subjects research and help streamline the documentation associated with research.  Here are the significant changes:

Compound Authorizations

The current HIPAA Privacy Rule generally prohibits "compound authorizations," which are authorizations for use and disclosure of protected health information (PHI) that are combined with any other legal permission.  An exception to this general prohibition permits combining an authorization for use and disclosure of protected health information in a research study with any other written permission for the same study, including an informed consent to participate in the research.  However, until March 26, 2013, the effective date of the Final Rule, even the same study exception is unavailable if one of the authorizations or permissions conditions treatment, payment, enrollment in a health plan or eligibility for benefits on the individual's provision of the authorization (a "conditioned authorization"), and the other authorization or permission does not contain such a condition (an "unconditioned authorization").  The purpose of this limitation on certain compound authorizations was to ensure that individuals could decline the activity described in the unconditioned authorization, yet still receive the treatment, services or benefits outlined in the conditioned authorization.  For example, research may include both treatment as part of the clinical trial and the banking of tissue and associated PHI.  The subject often must sign an authorization for use of his or her PHI in order to receive the research-related treatment (a "conditioned authorization"), but he or she is free to sign or to decide not to sign the tissue and data banking authorization ("unconditioned authorization").

Under the current HIPAA rule, a single authorization form cannot be used in this situation.  Instead, the covered entity must obtain two separate authorizations from research subjects:  one allowing use and disclosure of PHI to receive the research-related treatment and another allowing use and disclosure of PHI for the tissue and data banking.  Many researchers and research institutions expressed concerns about the additional paperwork and confusion that results from the separate form requirement.  In addition, they expressed concerns about the inconsistency of the current HIPAA rule with the Common Rule informed consent requirements (45 CFR Part 46) and with research documentation requirements outside the United States.

In response to these concerns, the Final Rule allows a covered entity to combine, in one form, conditioned and unconditioned authorizations for research,1 provided that the authorization clearly differentiates between the conditioned and unconditioned components and clearly allows the subject the option to participate in the unconditioned research activities.  These changes will allow covered entities to combine authorizations for use and disclosure of PHI for clinical trials and related tissue and data banking activities, as well as in other common research scenarios, such as a clinical trial involving an optional pharmacokinetics sub-study or a tissue banking protocol that permits future secondary research use of the data.

The Final Rule gives covered entities, researchers and institutional review boards discretion regarding how authorizations distinguish between conditioned and unconditioned activities.  In Commentary to the Final Rule, the Department of Health and Human Services (HHS) noted that a check-box or extra page explaining the "unconditioned" activity may be appropriate – but the Final Rule allows covered entities to determine the best approach.2

Authorization for Future Research Use and Disclosure

In the preamble to the Final Rule, HHS reversed its prior interpretation of the Privacy Rule that a research authorization must be study-specific and therefore may not include authorization for future research use.  As HHS explained, this interpretation was based on a concern that individuals would not have sufficient information to make truly informed decisions about the future research.  This interpretation, however, encumbered secondary research and diverged from Common Rule standards regarding subjects' informed consent for future research.

Under HHS's modified interpretation in the Final Rule, an authorization for the use or disclosure of PHI for research purposes does not have to be study-specific.  Rather, in order to satisfy the requirement that an authorization include a description of each purpose of the requested use or disclosure, an authorization for uses and disclosures of PHI for future research purposes must describe those purposes in a manner such that it would be reasonable for the individual to expect that his or her PHI could be used or disclosed for such future research.  The Final Rule gives covered entities, researchers, and IRBs flexibility to determine how to adequately describe the future research purpose, the information to be used or disclosed for the future research, and the recipients of the PHI for the future research.  In addition, HHS specifically noted that a description of the PHI to be used for the future research may include information collected beyond the time of the original study.  Finally, HHS stated that covered entities and researchers may rely on an IRB-approved consent obtained prior to the effective date of the Final Rule that reasonably informs individuals about future research, as long as the informed consent is combined with a HIPAA-compliant authorization.  HHS may issue additional guidance with respect to revocations of authorizations for future research uses.

Decedents' Protected Health Information

The Final Rule modifies the privacy protections applicable to decedents' health information.  Currently, the Privacy Rule requires covered entities to safeguard the privacy of a decedent's PHI indefinitely, in the same manner required for the PHI of living individuals.  If an authorization is required for a particular use or disclosure of PHI, the covered entity must obtain the authorization from the decedent's personal representative.  Under the Final Rule, any information that would otherwise constitute PHI of a decedent under 45 CFR § 160.201 ceases to be PHI 50 years after the death of the decedent.  This declassification will benefit research, as it can be burdensome to locate the personal representative of a decedent to obtain an authorization for use of the decedent's health information for research, especially if a significant period of time has passed since the individual's death.  HHS determined that 50 years is sufficient time to account for the privacy interests of living individuals related to the decedent.

Conclusions and Recommendations

The Final Rule provisions discussed above have important implications for research:

  • The changes concerning compound authorizations will alleviate administrative burdens on clinical trial subjects and researchers and facilitate harmonization with the Common Rule and global requirements for research documentation.
  • The revised interpretation regarding authorization for future research use will remove barriers on researchers' ability to use data for future research purposes – some of which cannot even be contemplated at the time the data is gathered, but which could hold great promise to advance science and medical care.
  • The declassification as "PHI" of certain information of decedents over time will ease researchers' ability to perform research using such information.

Researchers, research institutions and research sponsors have until September 23, 2013, to come into full compliance with the Final Rule.  In order to take advantage of the enhanced efficiencies in research initiatives that the Final Rule provides, however, those involved in research should begin revising research policies, procedures and forms now.  In addition, those involved in research should keep abreast of future regulatory developments and guidance on these and other issues, such as revocation of authorizations of use of PHI for future research use, additional guidance related to research use of genetic information, and harmonization of Final Rule provisions with FDA standards for informed consent.


1 This provision does not allow for the use of compound authorizations for research that involves the use or disclosure of psychotherapy notes.

2 The Commentary notes, however, that the Final Rule does not permit a combined authorization that allows the individual to opt out of the unconditioned research activities only (e.g., "check here if you do NOT want your data provided to the biospecimen bank."), because such an opt-out provision does not provide individuals a clear ability to authorize the optional research activity, and may be viewed as coercive.  Moreover, as HHS further explained, the Final Rule does not remove the requirement that an individual must affirmatively authorize the unconditioned research activities; it simply provides flexibility to streamline the authorization process by combining forms.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.